Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease

Mathilde Boussac¹, Florent Faggianelli², Estelle Harroch³, Alexandre Eusebio², Margherita Fabbri^{1

3}, Fabienne Ory-Magne^{1

3}, Emeline Descamps^{1

4}, Olivier Rascol^{1

3}, Chloé Laurencin⁵, Ana-Raquel Marques⁶, Mathieu Anheim^{7

8

9}, Bruno Giordana¹⁰, Lucie Hopes¹¹, Caroline Moreau¹², Anne-Sophie Rolland¹², David Devos¹², David Maltête¹³, Solène Ansquer¹⁴, Elodie Hainque¹⁵, Sophie Drapier¹⁶, Jean-Philippe Brandel¹⁷, Tiphaine Rouaud¹⁸, Dominique Guehl^{19

20}, Bechir Jarraya²¹, Mélissa Tir²², Tatiana Witjas², Jean-Philippe Azulay², Christine Brefel-Courbon^{1

3}; PREDISTIM study group

Affiliations

¹ Toulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.
² Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
³ Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.
⁴ CNRS, Toulouse, France.
⁵ Service de Neurologie C, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Lyon, France.
⁶ Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, IGCNC, Institut Pascal, Clermont-Ferrand, NS-Park/F-CRIN Network, France.
⁷ Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg and NS-Park/FCRIN Network Strasbourg, France.
⁸ Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, and NS-Park/FCRIN Network Strasbourg, France.
⁹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, and NS-Park/FCRIN Network, France.
¹⁰ Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
¹¹ Neurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network.
¹² Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
¹³ Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.
¹⁴ Service de neurologie, CHU POITIERS; CIC INSERM 1402, CHU POITIERS, Poitiers, France.
¹⁵ Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, F-75013, Paris, France.
¹⁶ CHU Pontchaillou, service de neurologie, CiC Inserm 1414, Rennes, France.
¹⁷ Department of Neurology, Hospital Fondation Rothschild, Paris, France.
¹⁸ Department of Neurology, CHU de Nantes, NS-Park/F-Crin network, Nantes, France.
¹⁹ Service de Neurophysiologie Clinique de l'enfant et de l'adulte, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
²⁰ Université de Bordeaux, Institut des Maladies Neurodégénératives (IMN, CNRS UMR5393), 33076, Bordeaux, France.
²¹ Pôle Neurosciences, Foch Hospital, Suresnes; Université Paris-Saclay, UVSQ, INSERM U992, CEA Paris-Saclay, Neurospin, France.
²² Service de Neurologie, Centre Expert de la maladie de Parkinson, CHU Amiens, Amiens, France.

PMID: 40576528
DOI: 10.1177/1877718X251354932

Free article

Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease

Mathilde Boussac et al. J Parkinsons Dis. 2025 Aug.

Free article

. 2025 Aug;15(5):1007-1018.

doi: 10.1177/1877718X251354932. Epub 2025 Jun 27.

Authors

Affiliations

¹ Toulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.
² Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
³ Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.
⁴ CNRS, Toulouse, France.
⁵ Service de Neurologie C, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Lyon, France.
⁶ Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, IGCNC, Institut Pascal, Clermont-Ferrand, NS-Park/F-CRIN Network, France.
⁷ Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg and NS-Park/FCRIN Network Strasbourg, France.
⁸ Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, and NS-Park/FCRIN Network Strasbourg, France.
⁹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, and NS-Park/FCRIN Network, France.
¹⁰ Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
¹¹ Neurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network.
¹² Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
¹³ Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.
¹⁴ Service de neurologie, CHU POITIERS; CIC INSERM 1402, CHU POITIERS, Poitiers, France.
¹⁵ Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, F-75013, Paris, France.
¹⁶ CHU Pontchaillou, service de neurologie, CiC Inserm 1414, Rennes, France.
¹⁷ Department of Neurology, Hospital Fondation Rothschild, Paris, France.
¹⁸ Department of Neurology, CHU de Nantes, NS-Park/F-Crin network, Nantes, France.
¹⁹ Service de Neurophysiologie Clinique de l'enfant et de l'adulte, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
²⁰ Université de Bordeaux, Institut des Maladies Neurodégénératives (IMN, CNRS UMR5393), 33076, Bordeaux, France.
²¹ Pôle Neurosciences, Foch Hospital, Suresnes; Université Paris-Saclay, UVSQ, INSERM U992, CEA Paris-Saclay, Neurospin, France.
²² Service de Neurologie, Centre Expert de la maladie de Parkinson, CHU Amiens, Amiens, France.

PMID: 40576528
DOI: 10.1177/1877718X251354932

Abstract

BackgroundParkinson's disease (PD) patients on dopaminergic drugs may experience non-motor fluctuations (NMFs) which are often heterogeneous and respond variably to treatments.ObjectiveWe evaluated if personality was associated to NMFs and could modulate the NMFs responsiveness to dopaminergic medication and deep brain stimulation of the sub-thalamic nucleus (STN-DBS).MethodsFrom the PREDISTIM cohort, personality dimensions of 235 PD patients were assessed by the Temperament and Character Inventory (TCI) before STN-DBS (V0). NMFs were evaluated using the NMFs Severity Scale at V0 and one year after STN-DBS (V1). Linear regression models were performed between TCI dimensions and NMFs at V0; and logistic regression models were done between TCI dimensions and 1) groups of dopa-sensitive patients (responders to ON medication at V0) versus non-dopa-sensitive ones, and 2) responders versus non-responders to STN-DBS at V1. Odds ratios (OR) were also calculated.ResultsSignificant associations were found between two TCI personality dimensions ("Harm Avoidance" and "Self-Directedness") and severity of NMFs in OFF medication at V0: PD patients with higher Harm Avoidance and lower Self-Directedness scores having more NMFs. TCI personality dimensions were not associated with the dopa-sensitivity while Novelty Seeking was significantly associated with the STN-DBS-responder group for the psychiatric (OR = 1.09 [1.02-1.17]) and for the dysautonomic NMFs (OR = 1.11 [1.04-1.18]).ConclusionsCertain personality dimensions (Harm Avoidance and Self-Directedness) are associated with NMFs severity at baseline, and PD patients with high Novelty Seeking seem to be better candidates for NMFs improvement after STN-DBS.

Keywords: Non-motor fluctuations; Parkinson's disease; Personality; Temperament and Character Inventory.

Plain language summary

Non-motor fluctuations are highly invalidating for patients with Parkinson's disease and their response to treatments is variable. This new research examined personality dimensions impact on non-motor fluctuations and their responsiveness to dopaminergic medication and to deep brain stimulation. Two hundred and thirty-five patients with Parkinson's disease participated in the study and filled out several questionnaires to score their personality dimensions and their non-motor fluctuations severity before and after one year of deep brain stimulation. Comparisons were done between different groups of patients according to their response to dopaminergic treatments and to deep brain stimulation. As results, patients with personality traits of high “Harm Avoidance” (more anxious individuals) and low “Self-Directedness” (less goal-oriented individuals) had globally more non-motor fluctuations, and the personality dimension of “Novelty Seeking” (impulsive individuals) was related to a better non-motor fluctuations responsiveness to deep brain stimulation. Hence, non-motor fluctuations are associated with some specific personality dimensions on top of early onset of Parkinson's disease, long disease-duration, high doses of levodopa and female gender. Moreover, Parkinson's disease patients with impulsive-like personality seem to be better candidates for non-motor fluctuations improvement after deep brain stimulation.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Data availability statementThe data used in this study is not our individual propriety. It comes from the cohort of a multicentric study. Therefore, the data can only be available on request to Research and Innovation unit of Lille University Hospital Center (David Devos: David. DEVOS@chru-lille.fr), once all the data has been analyzed.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- IOS Press
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease

Affiliations

Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease

Authors

Affiliations

Abstract

Plain language summary

Conflict of interest statement

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous